Synthesis and in vivo distribution of 2-deoxy-2-aminodiglucose-prednisolone conjugate (DPC)

In order to develop a novel kidney-targeted drug delivery system, a small molecular carrier (2-deoxy-2-aminodiglucose) was synthesized, and then the 2-deoxy-2-aminodiglucose-prednisolone conjugate (DPC) was synthesized to verify the kidney targeting capability of the carrier. Both 2-deoxy-2-aminodiglucose and DPC were confirmed by NMR and MS spectrum. The tissue distribution studies showed that DPC presented an excellent kidney targeting property in vivo, compared with prednisolone group, 4.9-fold of drug concentration in kidney was observed in the DPC group. Thus, it indicated that 2-deoxy-2-aminodiglucose could be a potential carrier for kidney-targeted drug delivery.